GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated November 12, 2025, reports on the status of three employee share schemes for the six-month period from May 1, 2025, to October 31, 2025. The filing serves as a regulatory update on unallotted securities under specific UK-listed plans.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the movement of securities within employee compensation schemes.
Material Changes and Scheme Activity
The following changes occurred in unallotted securities balances during the reporting period:
- GlaxoSmithKline plc 2017 Deferred Annual Bonus Plan: No securities were issued or allotted. The balance of unallotted securities remained constant at 115,518.
- GlaxoSmithKline plc Share Save Plan 2012: 134,547 securities were issued/allotted. The balance of unallotted securities decreased from 270,315 to 135,768.
- GlaxoSmithKline plc Share Save Plan 2022: 47,674 securities were issued/allotted. The balance of unallotted securities decreased from 951,791 to 904,117.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risks, contingencies, or unusual items. The document is a statutory return regarding share scheme administration.
Investor Verification Points
- Verify the total number of shares issued under the Share Save Plans (2012 and 2022) against the company's broader capitalization table.
- Confirm that the reduction in unallotted shares aligns with expected vesting schedules for the respective plans.
- Note that no new shares were added to the block schemes during this period.